Evidence map›Paper›PMID 28416638›Full record

ArticleMolecular and cellular biology2017

Eya2, a Target Activated by Plzf, Is Critical for

Ryoichi Ono, Masahiro Masuya, Satomi Ishii, Naoyuki Katayama, Tetsuya Nosaka

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and cellular biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. All eyes on Eya: A unique transcriptional co-activator and phosphatase in cancer.Biochimica et biophysica acta. Reviews on cancer · 2024
    Review
  3. Function of PML-RARA in Acute Promyelocytic Leukemia.Advances in experimental medicine and biology · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ryoichi OnoDepartment of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine, Tsu, Mie, Japan onor-tky@umin.net nosaka@doc.medic.mie-u.ac.jp.
Masahiro MasuyaDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
Satomi IshiiDepartment of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
Naoyuki KatayamaDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
Tetsuya NosakaDepartment of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine, Tsu, Mie, Japan onor-tky@umin.net nosaka@doc.medic.mie-u.ac.jp.
Mie University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PLZF is a transcription factor that confers aberrant self-renewal in leukemogenesis, and the

Indexed as

Gene Expression Regulation, NeoplasticAnimalsCell DifferentiationCells, CulturedCell Transformation, NeoplasticHematopoietic Stem CellsHumansIntracellular Signaling Peptides and ProteinsLeukemia, Myeloid, AcuteMiceMice, Inbred C57BLNuclear ProteinsOncogene Proteins, FusionPromoter Regions, GeneticProtein Tyrosine PhosphatasesEya2 protein, mouseIntracellular Signaling Peptides and ProteinsNuclear ProteinsOncogene Proteins, FusionPLZF-RARalpha fusion protein, mouseProtein Tyrosine Phosphatasesleukemia

Identifiers

PMID28416638
PMCPMC5472835
OpenAlexW2607245627

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.